Personalized T-Cell therapy takes on pancreatic cancer
NCT ID NCT06549751
First seen May 14, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This early-phase trial tests a new treatment called MT-601 for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. MT-601 uses a patient's own immune cells, specially trained to attack multiple cancer targets, given alongside chemotherapy. The main goals are to check safety and see if the treatment can shrink tumors or slow the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas MD Anderson
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.